VA Awards $1.5M To Study MDMA for PTSD

Veterans Affairs officials announced on Tuesday a $1.5 million grant to explore MDMA-assisted therapy as a treatment for post-traumatic stress disorder (PTSD) and alcohol use disorder among veterans. This marks the department’s first government-funded research into the potential benefits of psychedelics in over 50 years.

Earlier this year, the VA revealed plans to study the therapeutic potential of psychedelic compounds for veterans battling mental health issues. However, until now, no funding had been allocated to these efforts.

For years, advocates have championed the mental health benefits of compounds like MDMA, also known as methylenedioxymethamphetamine. Recognized for its potential to address trauma-related disorders, MDMA received a “breakthrough therapy” designation from the U.S. Food and Drug Administration (FDA) in 2017, signaling its promise as a transformative treatment for PTSD.

The newly funded initiative will be conducted at the Providence VA Medical Center in Rhode Island and the West Haven VA Medical Center in Connecticut. Researchers from prestigious institutions, including Brown University and Yale University, will oversee the project, which is set to begin enrolling participants early next year.

“This study will provide valuable insights into the potential of MDMA-assisted therapy as a treatment for veterans,” said Dr. Shereef Elnahal, VA Under Secretary for Health. “VA is at the forefront of clinical research into innovative solutions for veterans’ mental health.”

The study is part of a broader VA effort to evaluate the efficacy and safety of psychedelic compounds in treating mental health conditions. Officials confirmed that this initial research would not be the department’s only exploration into psychedelics.

The treatment sessions will adhere to rigorous safety protocols, using pharmaceutical-grade MDMA in controlled clinical environments. The study is expected to span five years, ensuring thorough investigation and comprehensive results.

Despite growing interest in psychedelics for mental health, VA officials caution veterans against self-medicating with these substances. “Veterans are strongly encouraged to consult with their healthcare providers before trying any new medications or therapies,” the department emphasized.

This pivotal study reflects the VA’s commitment to exploring innovative treatments for the complex mental health challenges many veterans face. With its potential to redefine therapeutic approaches to PTSD and alcohol use disorder, the research could herald a new era of care for America’s veterans.